A detailed history of Marshall Wace, LLP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 50,570 shares of RLMD stock, worth $19,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,570
Previous 156,619 67.71%
Holding current value
$19,216
Previous $469,000 65.25%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $243,912 - $462,373
-106,049 Reduced 67.71%
50,570 $163,000
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $150,165 - $253,179
-51,251 Reduced 24.66%
156,619 $469,000
Q1 2024

May 15, 2024

BUY
$3.1 - $6.8 $168,469 - $369,546
54,345 Added 35.4%
207,870 $966,000
Q4 2023

Feb 14, 2024

BUY
$2.45 - $4.22 $376,136 - $647,875
153,525 New
153,525 $635,000
Q3 2022

Nov 14, 2022

BUY
$18.3 - $37.02 $1.76 Million - $3.56 Million
96,254 New
96,254 $3.57 Million

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.